What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Orthocell

Home
Australia
Perth, WA
Orthocell

Orthocell (ASX: $OCC) is a regenerative medicine company producing innovative products to empower the body to heal tendon, cartilage and soft tissue injuries.

Remplir™ is a collagen nerve wrap that protects nerves and supports healing. Striate+ is used for guided bone regeneration. Orthocell also develops cell therapies for tendon (OrthoATI™) and cartilage repair (OrthoACI™), plus SmrtGraft™ for tendon reconstruction.

19/12/2025

We are heading to the American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery 2026 annual meetings.

Join Orthocell on the exhibition floor. Visit us at Booth #115 and see Remplir™ up close.

We are also hosting a dedicated Industry Forum: What Links Regenerative Medicine and Peripheral Nerve Repair? A Biomaterial Built to Solve Real Surgical Challenges.

📍 Ga***rd Pacific Resort, Port 3 Ballroom
🗓 15 January 2026
⏰ 1.00pm–2.30pm

Come for lunch. Hear from experienced surgeons. Explore real-world clinical insights. Discover how innovations in regenerative medicine are transforming peripheral nerve repair.

If you are attending AAHS, ASPN, or ASRM, this session is for you.

Stop by the stand. Join the forum. Be part of the conversation.

14/12/2025

Orthocell has submitted a regulatory application to the British Standards Institution (BSI) seeking approval to commercially distribute Remplir™ in the European Union and United Kingdom, a combined nerve repair market valued at approximately US$750 million and comprising an estimated 500,000 peripheral nerve repair procedures each year.

The application seeks CE and UKCA certification under EU and UK Medical Device Regulations (MDR), with regulatory approval expected in the third quarter of calendar year 2026.

This submission is supported by compelling real-world clinical evidence from Orthocell’s recent Remplir post-market clinical follow-up study, which demonstrated an overall treatment success rate of 81.1% across nerve repair procedures. The data forms a critical component of the technical documentation required for MDR certification.
Orthocell CEO and MD, Paul Anderson said

“We are thrilled to submit our EU and UK regulatory application for Remplir, marking an important milestone in our global expansion strategy. The application is underpinned by the compelling 81.1% treatment success rate from our recent Real World Evidence study, together with previously published clinical data and rapidly increasing surgeon use.

“We expect to receive clearance from the BSI in 3Q of CY 2026 and in the interim, we’ll be focused on advancing our go-to-market strategy to be prepared to generate sales as soon as possible thereafter. The EU and UK has the potential to be our second largest market after the US and is therefore a pivotal component of our global expansion strategy.”

🔗Read the ASX release: https://bit.ly/48Dr55N

$OCC

09/12/2025

Orthocell has announced that it has completed the first commercial sales of Remplir™ in Hong Kong, representing a key milestone in the Company’s Asian growth strategy.

These initial sales follow the successful introduction of Remplir in Hong Kong, including its first surgical use and strong reception at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress. These first sales to MontsMed provide immediate in-market availability and are expected to support multiple downstream sales as surgeons adopt the technology.

Hong Kong represents a strategically important entry point into the Guangdong–Hong Kong–Macao Greater Bay Area (GBA), one of Asia’s most dynamic healthcare regions with a population of approximately 100 million people.

Orthocell’s Chief Scientific Officer, Professor Minghao Zheng, is currently in Hong Kong delivering distributor onboarding and scientific training with the MontsMed team. This program is designed to support MontsMed’s early commercial activities by empowering clinical and sales teams to drive engagement with specialist surgeons.

Orthocell CEO and MD, Paul Anderson said:

“First Hong Kong sales represent an important commercial milestone for Orthocell and a strong validation of Remplir’s clinical value. We are well positioned to support MontsMed in driving adoption across leading hospitals in Hong Kong and the Greater Bay Area. We are executing our commercialisation strategy with discipline, and today’s achievement marks another step forward in establishing Remplir as a new standard of care in peripheral nerve repair.”

🔗Read the ASX release: https://bit.ly/4ppRB8t

$OCC

26/11/2025

🖥️ Ausbiz Capital | Investor Connect webinar

Orthocell CEO & MD, Paul Anderson, will be presenting at the Ausbiz Capital Investor Connect Session on Thursday 27 November at 1.00 PM (AEDT).

This free virtual event brings together CEOs from ASX-listed companies to share progress updates and engage directly with the Ausbiz investor community.

Paul will share an update on Orthocell’s commercialisation progress, regulatory plans, and the opportunities ahead as we advance our world-leading regenerative medicine products.

When: 27 November 2025 at 1:00 PM Sydney (AEDT) / 10am Perth (AWST)
🔗 Register to attend: https://info.ausbiz.com.au/connectnov25

$OCC

20/11/2025

Momentum is growing for Remplir™ in nerve-sparing prostate cancer surgery, with around 100 surgeries now performed using the flagship nerve repair device.

Adoption among Australian urologists is accelerating, with Remplir being used to support postoperative nerve protection and recovery. Surgeons are applying the collagen wrap during robotic-assisted radical prostatectomy with the aim of improving erectile function and urinary continence following surgery.

This emerging application represents a significant commercial opportunity, with the potential to expand Orthocell’s U.S. total addressable market from US$1.6B to approximately US$2B.

To support this opportunity, Orthocell is setting up a commercialisation advisory board and investing in further research to strengthen the scientific evidence base for this new application of Remplir.

Initial clinical performance data from nerve-sparing procedures using Remplir across Australia will be released once compiled.

Orthocell CEO and MD, Paul Anderson, said:
“We’re thrilled to see Remplir being adopted by urologists in Australia for nerve-sparing prostate surgery, reflecting its broader potential in peripheral nerve protection and repair. This demonstrates the utility of the product and represents the potential for a meaningful step forward in improving patient outcomes following these complex surgeries.”

Read the ASX release: https://bit.ly/4piU1W1

$OCC

19/11/2025

Orthocell extends its congratulations to Non-Executive Director, Dr Ravi Thadhani, on his recent election to the U.S. National Academy of Medicine.

His election to the Academy – considered one of the highest honours in the fields of health and medicine – reflects the global recognition of his pioneering work in medical science and his commitment to advancing clinical innovation.

Dr Thadhani’s election follows his recent appointment as Executive Vice President of Clinical Affairs & Chief Medical Officer at Cedars-Sinai Health System. In this role, he will oversee clinical quality and safety, medical affairs, and standards of care across Cedars-Sinai and its affiliated hospitals.

These appointments are a powerful testament to the strength of Dr Thadhani’s vision and influence in the healthcare and biomedical space – qualities that also enrich his contributions to the Orthocell Board.

To learn more about Dr Thadhani’s new appointment at Cedars Sinai, visit 👉 https://ceda.rs/4o5pHO6

$OCC

14/11/2025

🔹 ACSEP 2025 🔹

Our team is on the Gold Coast this week for the ACSEP 2025 Annual Scientific Conference, connecting with sport and exercise physicians from across Australia and New Zealand.

This meeting is a key forum for discussing the latest advancements in sport and exercise medicine, including innovative approaches to tendon injury management and repair.

Product Specialist Ellis Taylor and Business Development Manager Trevor Turnbull are on the ground showcasing our tendon cell therapy technology and speaking with clinicians about how our biologic solutions may support improved outcomes for patients with chronic tendon injuries.

If you’re attending ACSEP, drop by to say hello.

$OCC

04/11/2025

Orthocell is expanding its presence in Canada, appointing a second distributor for its flagship nerve repair device, Remplir™. The appointment completes national coverage across the US$75 million Canadian market, ensuring access for patients and healthcare providers nationwide.

The newly appointed Ontario-based distributor will manage Remplir™ across all provinces outside of Alberta and British Columbia, which continue to be serviced by Orthocell’s existing distributor.

First Canadian sales are expected this quarter following last month’s successful launch at the American Society for Surgery of the Hand in Vancouver. Rollout activities in Canada will be overseen by Orthocell’s US-based Marketing and Medical Education team.

Orthocell CEO and MD, Paul Anderson said:

“We’re very pleased to expand our Canadian distributor presence beyond Alberta and BC with this new appointment opening up the entire Canadian market.

Each new distributor appointment is an important step, initiating targeted sales and marketing efforts in their territories and bringing us closer to generating new revenue streams.”

🔗 Read the ASX release: https://bit.ly/48Ye5Iv

$OCC

03/11/2025

Orthocell has announced the successful completion of the first Remplir™ surgical case in Hong Kong and the official launch of their flagship nerve repair medical device at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress.

These achievements mark the start of clinical use and commercial sales in Hong Kong, following the appointment of MontsMed as exclusive in-country distributor. The launch event introduced Remplir to key opinion leaders and specialists in orthopaedic and reconstructive surgery, highlighting its clinical advantages in peripheral nerve repair.

A special shout out to Maier, Orthocell’s Vice President, Global Commercialization & Professional Engagements, who flew out Thursday night to support the launch and went straight to the hospital for the first case.

🔗 Read the ASX release: https://bit.ly/4nFLVWr

$OCC

29/10/2025

Congratulations to Professor Minghao Zheng, Orthocell’s Co-Founder and Chief Scientific Officer, on his election as a Fellow of the Australian Academy of Health and Medical Sciences (AAHMS) - one of the nation’s highest honours for leaders in health and medical research.

This Fellowship acknowledges Professor Zheng’s outstanding contributions to regenerative medicine and translational science, and his pivotal role in developing the technologies that underpin Orthocell’s medical device portfolio.

His pioneering research into collagen scaffolds and autologous cell therapies led to the creation of a next-generation collagen medical device platform technology which facilitates tissue reconstruction and healing in a variety of orthopaedic and reconstructive applications , and Ortho-ATI™, a regenerative cell therapy for chronic tendon injury. Together, these innovations continue to shape Orthocell’s mission to deliver advanced solutions for tissue repair and restoration of mobility.

Professor Zheng’s election to the Academy reflects a remarkable career dedicated to improving patient outcomes and advancing Australia’s reputation for world-class medical innovation.

Orthocell extends its warmest congratulations to Professor Zheng on this distinguished honour.

$OCC

Address

Building 191 Murdoch University South Street
Perth, WA
6150

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Website

https://orthocell.com/

Alerts

Be the first to know and let us send you an email when Orthocell posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Orthocell:

Shortcuts

Featured

Cottesloe Naturopathic Clinic
Hug Pelvic Physio
4 Antony Street Palmyra